Continuous versus Intermittent Neuroleptic Therapy in Schizophrenia Anthony G. JolleySteven R. Hirsch Leading Article 19 October 2012 Pages: 331 - 339
Minimising the Risks of PUVA Treatment Marinus C. G. van PraagLarissa N. L. TsengBert Jan Vermeer Commentary 19 October 2012 Pages: 340 - 349
Overview of the Tolerability Profile of Clarithromycin in Preclinical and Clinical Trials David R. P. GuayD. Reid PattersonJ. Carl Craft Review Article 19 October 2012 Pages: 350 - 364
Systemic and Local Tolerability of Ophthalmic Drug Formulations François-Claude HuguesClaire Le Jeunne Review Article 19 October 2012 Pages: 365 - 380
A Risk-Benefit Assessment of Tamoxifen Therapy William H. CatherinoV. Craig Jordan Review Article 19 October 2012 Pages: 381 - 397